Moderna says US FDA refuses to review its influenza vaccine
ReutersFeb 10, 2026 11:06 PM
Feb 10 (Reuters) - Moderna MRNA.O said on Tuesday the U.S. Food and Drug Administration will not review its approval application for its influenza vaccine.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
After $20B Debt Sale, Google’s Rare 100-Year Bond Sparks Scrutiny: Has AI Drained the Tech Giant’s Coffers?
TradingKey - According to a Financial Times report, Google parent Alphabet (GOOG)(GOOGL) is planning to issue bonds denominated in British pounds and Swiss francs, which may include the first 100-year GBP bond of this century.TradingKey
10 hours ago
What is behind the continuous plunge in Japanese government bonds?
TradingKey - Recently, long-term Japanese government bonds (JGBs) have faced a sustained sell-off, causing prices to plunge and yields to surge to nearly 27-year highs. On January 20, the 10-year JGB yield climbed to 2.330% at one point, marking its highest level since February 1999. On February 9,TradingKey
14 hours ago
SpaceX IPO Approaching: Will EchoStar Be a Good Buy in 2026?
TradingKey - Today, EchoStar (SATS) is a hybrid story around legacy consumer communications and a high-profile private space play. As a result of its merger with DISH, the company offers satellite TV services and the wireless brand Boost Mobile, in addition to spectrum assets and wholesale network aTradingKey
16 hours ago
Market Cap Erased, Successive Downgrades? Wall Street Is Re-evaluating Microsoft’s AI Future
TradingKey - In early 2026, tech giant Microsoft (MSFT) got off to a less-than-ideal start. Year-to-date, its share price has fallen by more than 12%, and its total market capitalization briefly dipped below the $3 trillion mark. As a former leader in technological innovation, why has Microsoft suddenly appeared to stumble in the current AI wave? What are the underlying issues?TradingKey
19 hours ago
